Núria Nadal-Gratacós
@nurianadalg.bsky.social
Assistant Professor at UB. Interested in Psychedelics, Synthetic Cathinones and other NPS. 👩🏻🔬🔬🐭
A fantastic day discussing the latest advances in psychoactive substance research at our symposium! Thanks to all the speakers, attendees, and the Càtedra UB – Dr. Antoni Esteve i Subirana de Recerca en Farmacologia for making it possible. Looking forward to the next edition!
Registration form: forms.office.com/e/TwprwjYkrN
Microsoft Forms
forms.office.com
Núria Nadal-Gratacós@nurianadalg.bsky.social · 4mo agoIf you're coming to Barcelona for #FENS2026 (or simply looking for an excuse to visit sunny Barcelona), we'd love to see you at our symposium held at @farmaciaub.bsky.social on July 9! Looking forward to a great day of discussions on NPS and psychedelic research with colleagues from across Europe!
If you're coming to Barcelona for #FENS2026 (or simply looking for an excuse to visit sunny Barcelona), we'd love to see you at our symposium held at @farmaciaub.bsky.social on July 9! Looking forward to a great day of discussions on NPS and psychedelic research with colleagues from across Europe!
NextNPS-UB@nextnps-ub.bsky.social · 4mo agoJoin us on July 9 at the Faculty of Pharmacy and Food Sciences (UB, Barcelona) for the symposium "From Classical to Novel Psychoactive Substances: Toxicological Risks and Therapeutic Opportunities". Featuring researchers from across Europe sharing the latest advances in NPS and psychedelic research.
Join us on July 9 at the Faculty of Pharmacy and Food Sciences (UB, Barcelona) for the symposium "From Classical to Novel Psychoactive Substances: Toxicological Risks and Therapeutic Opportunities". Featuring researchers from across Europe sharing the latest advances in NPS and psychedelic research.
🎓 Congratulations to our PhD candidate Martalu D. Pazos, who will represent the University of Barcelona in the international 3 Minute Thesis competition (Coimbra Group)! A fantastic achievement and a great opportunity to share her research with a broad audience 👏
Excited to share our new publication: Neurochemical and Behavioral Evidence of High Abuse Liability of 3F-NEB, a Novel Synthetic Cathinone Grateful for the support and teamwork during this journey. @msolinas.bsky.social Read it here: www.sciencedirect.com/science/arti...
Neurochemical and Behavioral Evidence of High Abuse Liability of 3F-NEB, a Novel Synthetic Cathinone
Synthetic cathinones constitute a major class of New Psychoactive Substances (NPS) with significant abuse potential. Within this class, 3F-N-ethylbuph…
sciencedirect.com
Excited to share our new paper in ACS Chemical Neuroscience! 🎉 In this work, we study MDMA analogues, exploring their pharmacological properties and potiential for safer therapeutic use. A great collaboration we’re very happy about! Read it here: pubs.acs.org/doi/10.1021/...
Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA’s abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of MDMA analogues in which the 1,3-benzodioxole group is replaced by a 1,3-benzoxathiole, termed SDA and SDMA, compared to MDA and MDMA through in silico, in vitro, and in vivo assays. In vitro experiments using human embryonic kidney (HEK293) cells examined the interactions with monoamine transporters. SDA and SDMA showed similar profiles to MDMA at the serotonin transporter (SERT), while both inhibited dopamine (DAT) and norepinephrine (NET) transporters more potently, in line with in silico molecular docking fitness scores of binding. SDA and SDMA also showed increased potency in evoking efflux through SERT and DAT acting as partial releasers. SDA and SDMA exhibited a similar interaction profile with 5-HT2 receptors compared with their respective analogues. Metabolism studies revealed faster clearance rates for SDA and SDMA, in contrast to MDA and MDMA, which exhibited only weak degradation. In contrast to MDMA’s rewarding effects, SDMA did not induce significant effects in mice, while SDA only produced a significant preference for the drug-paired compartment at the lowest dose tested. Moreover, while SDMA shares similar locomotor and hyperthermic profiles as MDMA in mice, SDA induced increased hyperlocomotion and more sustained hyperthermia. In conclusion, these findings suggest that SDMA, with enhanced metabolic profiles and reduced abuse potential, is a promising candidate for further studies.
pubs.acs.org
Our new study characterizes 25C-NBF as a selective 5-HT2A agonist with psychoplastogenic and rapid antidepressant-like effects in rodents. So excited to see this work published in Molecular Psychiatry! Read it here: www.nature.com/articles/s41...
The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents - Molecular Psychiatry
Molecular Psychiatry - The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents
nature.com
We’re thrilled to share our paper， recently published in Molecular Psychiatry: “Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential” 
Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential - Molecular Psychiatry
Molecular Psychiatry - Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
nature.com
Excited to share that our book chapter “Psychedelics for the Treatment of Substance Use Disorder” is now published in Psychedelic Drugs – Therapeutic and Recreational Use (IntechOpen)! Read it here: www.intechopen.com/online-first...
Psychedelics for the Treatment of Substance Use Disorder
<p id="p1">Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organizati...
intechopen.com
Huge congrats to Dr. Pol Puigseslloses for successfully defending his PhD last Friday — the first psychedelic-themed thesis from our group! 🍄 We’re proud of you! #PhDDefense #Psychedelics
Just when you think you’ve seen it all… one of my undergrads builds a 3D model of the tail suspension test 🐭💫 Honestly, moments like this remind me why I love my job.
NextNPS-UB@nextnps-ub.bsky.social · last yr.One of @nurianadalg.bsky.social ‘s undergraduate students surprised her with this fantastic 3D model of the tail suspension test! 🐭🤩 We love seeing such creativity and appreciation from our students.
Hello Bluesky! 👋 We are a research group from @ub.edu focused on the neuropsychopharmacology of emerging psychostimulants and psychedelics. Our work bridges neuroscience and toxicology to better understand how these compounds affect the brain🧠.
